The "Fast Money" traders discuss their views on Biogen.
CNBC's Meg Tirrell reports on Theranos founder Elizabeth Holmes's efforts to make the case for her company's blood-testing device.
CNBC's Meg Tirrell reports the latest of what Pfizer CEO Ian Read has to say on biotech valuations, the election and more. The “Fast Money Halftime Report” traders and Stephanie Link, TIAA Global Asset Management, weigh in.
Recode's Kara Swisher discusses Theranos CEO Elizabeth Holmes' appearance at the AACC Conference to unveil a new blood testing device, the Uber China merger with rival Didi Chuxing and the Yahoo-Verizon deal.
The "Squawk Box" crew and CNBC's Meg Tirrell discuss some of the morning's most provocative headlines including Theranos CEO Elizabeth Holmes speaking out for the first time since being banned from operating a clinical lab.
Embattled Theranos CEO Elizabeth Holmes presents clinical data at the AACC Conference and unveils new technologies.
Discussing implied earnings moves in big pharma, including Pfizer, Allergan and more with CNBC contributor Mike Khouw. The "Fast Money" traders weigh in.
Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.
Biogen and Ionis Pharmaceuticals soar on a new muscle-disorder drug for babies, CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
With new questions emerging about the strength of the economy, will there be a potential cut in dividends? The "Fast Money Halftime Report" traders discuss.
CNBC's Jim Cramer explains why he is watching Celgene.
Jim Cramer explains what to watch ahead of the open including Ionis Pharmaceuticals and Biogen.
CNBC's Meg Tirrell reports on Theranos founder Elizabeth Holmes making her first public appearance since getting banned from operating a clinical lab.
GlaxoSmithKline and Alphabet's life sciences unit are creating a new company focused on fighting diseases.
The "Fast Money Halftime Report" panel joined by CNBC's Meg Tirrell discuss the future of microbiome medicine.
UK pharma giant records net loss for the second quarter but is set to gain from export-driven growth.
Andrew Witty, CEO of GlaxoSmithKline, says the firm has been investing in bio electronic medicine for the last few years.
CNBC's Bob Pisani looks at the day's market action, earnings, and why things seem to be holding up so well.
Greg Sarian, Hightower, says he favors the biotech sector right now.
LONDON, July 26- The heirs of Dolly the sheep are enjoying a healthy old age, proving cloned animals can live normal lives and offering reassurance to scientists hoping to use cloned cells in medicine. Dolly, cloning's poster child, was born in Scotland in 1996. "Overall, the results are suggesting that these animals are remarkably healthy," said Kevin Sinclair of the...